Mass Spectrometry & Spectroscopy
First NMR Analyser Designed Specifically for the Clinical Laboratory
Nov 16 2012
Agilent Technologies Inc have announced that it has entered into an exclusive supply agreement with LipoScience Inc to provide nuclear magnetic resonance (NMR) components for LipoScience’s Vantera Clinical Analyser. The analyser is the first fully-automated NMR diagnostic platform designed specifically for the clinical laboratory and cleared by the US Food and Drug Administration.
The Vantera Clinical Analyser, which recently received 510(k) clearance from the FDA, combines proprietary signal-processing algorithms and NMR spectroscopic detection to identify and quantify concentrations of lipoproteins and, potentially, small-molecule metabolites.
“We are extraordinarily pleased to join forces with LipoScience to provide key components for this leading-edge diagnostic platform,” said Nick Roelofs, President of Agilent’s Life Sciences Group.
“LipoScience is pioneering a new field of personalised diagnostics based on NMR technology. Broadening access to our proprietary diagnostic tests is central to our vision of becoming a clinical standard of care. We value Agilent’s NMR expertise and look forward to partnering with them in our efforts to decentralise our NMR clinical analyser to leading clinical laboratories and academic centres of excellence,” added Richard O. Brajer, CEO of LipoScience.
In This Edition Chromatography Articles - Comparing techniques for flow rate measurement in Liquid Chromatography Mass Spectrometry & Spectroscopy Articles - APGC: A Better Future with...
View all digital editions
Mar 14 2024 Brussels, Belgium
Mar 17 2024 Monterey, CA, USA
Mar 17 2024 New Orleans, LA, USA
Mar 18 2024 Barcelona, Spain
Mar 26 2024 Milan, Italy